Novartis Published P-III (SUNSHINE) and (SUNRISE) Trials Results of Cosentyx (secukinumab) for Hidradenitis Suppurativa in The Lancet
- The P-III (SUNSHINE) and (SUNRISE) trials evaluating Cosentyx (300mg, q2w/q4w) vs PBO in more than 1000 patients in 40 countries
- In both trials, patients treated with Cosentyx (300mg, q2w) achieved HiSCR (45.0% vs 33.7%) & (42.3% vs 31.2%) @16wks., Cosentyx (300mg, q4w) was superior to PBO (46.1% vs 31.2%) & (41.8% vs 33.7%)
- Treatment response rates continued to improve beyond the 1EPs analysis @16wk., 55% achieved a HiSCR measure @52wk., ≥60% were free of flares, and ≥50% reduction in pain. The safety results were consistent with the well-established profile of Cosentyx with no new signals & long-term efficacy & safety results were also seen who did not respond to biological therapies. The results have been submitted to regulatory authorities in the EU & US with decisions expected in 2023
Ref: Novartis | Image: Novartis
Related News:- Novartis’ Cosentyx (secukinumab) Receives the MHRA’s Marketing Authorisation for Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].